---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268840"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:02:20.033455+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q3 revenue $36.0M, net loss $0.30/sh; FY guidance reaffirmed

## Summary
- U.S. XPOVIO net product revenue $30.2M, down from $32.0M year-over-year due to PAP use and 340B discounts.
- Net loss of $34.5M ($0.30/sh) improved from $36.3M ($0.45/sh) in Q3 2022; cash $209.2M as of Sept 30, 2023.
- Full-year 2023 guidance held: total revenue $145-160M, XPOVIO net revenue $110-125M, non-GAAP opex $240-255M.
- NCCN elevated XVd to preferred category 1 for lenalidomide-refractory multiple myeloma after 1-3 prior lines.
- Entered clinical collaboration with BMS to evaluate mezigdomide + selinexor in R/R myeloma post T-cell therapies.

## SEC filing metadata
- accession: 0001193125-23-268840
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312523268840/0001193125-23-268840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312523268840/d578470d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268840
- JSON: https://secwatch.observer/filing/0001193125-23-268840.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268840.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported the quarter ended September 30, 2023 results: revenue $36.0 million. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2023
  - Revenue: $36.0 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue for the third quarter of 2023 was $36.0 million, compared to $36.1 million for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523268840/0001193125-23-268840-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.